Revolution Medicines (RVMD) Insider Patel Buys 3,127 Shares
Insider Sushil Patel purchased 3,127 shares of Revolution Medicines on June 18, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Sushil Patel bought 3,127 shares of Revolution Medicines, Inc. ($RVMD) on June 18, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $RVMD is up 9.3% after 1 week, up 10.7% after 1 month and up 9.2% to date (from the $162.99 close on Jun 18, 2026).
RVMD
Revolution Medicines, Inc.
Key Points
- Sushil Patel bought 3,127 shares of Revolution Medicines, Inc. on June 18, 2026.
- Revolution Medicines, Inc. traded near $169.51 on Wednesday with a market cap of $35.3 billion.
- Analysts maintain a strong buy consensus with a mean price target of $187.29.
Get $RVMD trade alerts by text
We text you when insiders, Congress or big funds trade $RVMD. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Revolution Medicines, Inc. alert may contain errors. Disclosures
Sushil Patel, an insider at Revolution Medicines, Inc. (NasdaqGS: RVMD), purchased 3,127 shares of the company on June 18, 2026. The stock was trading around $169.51 on Wednesday, reflecting the company's substantial market presence with a market cap of $35.3 billion.
Insider Buying and Selling at Revolution Medicines, Inc.
On June 18, 2026, several insiders at Revolution Medicines, including Sushil Patel, bought shares. Patel acquired 3,127 shares, while other insiders like Kim Lorence, Flavia Borellini, and Elizabeth Anderson also made similar purchases. These transactions were not part of any pre-planned 10b5-1 trading plans.
Revolution Medicines, Inc. Stock Down 11.2%
Shares of Revolution Medicines, Inc. traded near $169.51 on Wednesday. The company, with a market cap of $35.3 billion, is involved in the biotechnology sector, focusing on precision oncology. It has a forward P/E of -29.1 and a beta of 1.407. The stock's 52-week range is between $34.00 and $166.84, with a 50-day moving average of $146.50 and a 200-day moving average of $95.18. The company maintains a strong liquidity position with a current ratio of 6.80 and a quick ratio of 6.59.
Analysts Set New Price Targets
Analysts continue to show confidence in Revolution Medicines, with Evercore ISI Group maintaining a 'buy' rating and setting a price target of $220 on June 10. RBC Capital also maintained a 'buy' rating with a target of $182 on June 2. Overall, the analyst consensus remains strong buy with an average price target of $187.29 from 21 analysts.
About Revolution Medicines
Revolution Medicines, Inc. is a biotechnology company based in Redwood City, California. It focuses on developing targeted therapies for RAS-addicted cancers. The company is led by CEO Dr. Mark A. Goldsmith and employs 883 people. Revolution Medicines works on RAS(ON) inhibitors, which are in various stages of clinical development, aimed at treating solid tumors and other cancer types.
Bottom Line
Insider activity at Revolution Medicines, including the recent purchase by Sushil Patel, reflects ongoing interest in the company's growth potential. The stock's trading price and market cap indicate strong market confidence. Analysts' ratings and price targets suggest continued optimism about the company's future prospects. As always, note that insider and analyst actions are based on past data and should be considered as part of broader investment research.
Related Filing Alerts
Source: Sushil Patel's Form 4 filing on $RVMD (Jun 18, 2026). Find the original filing: RVMD Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts